{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:42:11Z","timestamp":1784612531609,"version":"3.55.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T00:00:00Z","timestamp":1584057600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T00:00:00Z","timestamp":1584057600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81573505"],"award-info":[{"award-number":["81573505"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008410","name":"Shanghai Municipal Population and Family Planning Commission","doi-asserted-by":"publisher","award":["2016ZB0301-01"],"award-info":[{"award-number":["2016ZB0301-01"]}],"id":[{"id":"10.13039\/501100008410","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Jing'an district Municipal Commission of Health and Family Planning","award":["20164Y0238"],"award-info":[{"award-number":["20164Y0238"]}]},{"name":"Huashan Hospital, Fudan University","award":["2014QD08"],"award-info":[{"award-number":["2014QD08"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s13318-020-00609-5","type":"journal-article","created":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T18:02:47Z","timestamp":1584122567000},"page":"453-466","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Population Pharmacokinetic Analysis of Tacrolimus in Adult Chinese Patients with Myasthenia Gravis: A Prospective Study"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0846-5377","authenticated-orcid":false,"given":"Jue","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Peng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7999-7162","authenticated-orcid":false,"given":"Zheng","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong-Bo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Ran","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Ying","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,13]]},"reference":[{"issue":"1","key":"609_CR1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1159\/000311012","volume":"35","author":"CH Lai","year":"2010","unstructured":"Lai CH, Tseng HF. Nationwide population-based epidemiological study of myasthenia gravis in Taiwan. Neuroepidemiology. 2010;35(1):66\u201371. https:\/\/doi.org\/10.1159\/000311012.","journal-title":"Neuroepidemiology."},{"issue":"3","key":"609_CR2","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1159\/000279334","volume":"34","author":"A McGrogan","year":"2010","unstructured":"McGrogan A, Sneddon S, de Vries CS. The incidence of myasthenia gravis: a systematic literature review. Neuroepidemiology. 2010;34(3):171\u201383. https:\/\/doi.org\/10.1159\/000279334.","journal-title":"Neuroepidemiology."},{"issue":"9340","key":"609_CR3","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/s0140-6736(02)11196-2","volume":"360","author":"JG O\u2019Grady","year":"2002","unstructured":"O\u2019Grady JG, Burroughs A, Hardy P, Elbourne D, Truesdale A. Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial. Lancet. 2002;360(9340):1119\u201325. https:\/\/doi.org\/10.1016\/s0140-6736(02)11196-2.","journal-title":"Lancet"},{"issue":"5","key":"609_CR4","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","volume":"8","author":"MN Meriggioli","year":"2009","unstructured":"Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009;8(5):475\u201390. https:\/\/doi.org\/10.1016\/S1474-4422(09)70063-8.","journal-title":"Lancet Neurol."},{"issue":"2","key":"609_CR5","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1177\/1756285615571873","volume":"8","author":"JL Cruz","year":"2015","unstructured":"Cruz JL, Wolff ML, Vanderman AJ, Brown JN. The emerging role of tacrolimus in myasthenia gravis. Ther Adv Neurol Disord. 2015;8(2):92\u2013103. https:\/\/doi.org\/10.1177\/1756285615571873.","journal-title":"Ther Adv Neurol Disord."},{"issue":"9","key":"609_CR6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1177\/1756285617721092","volume":"10","author":"L Zhou","year":"2017","unstructured":"Zhou L, Liu W, Li W, Li H, Zhang X, Shang H, et al. Tacrolimus in the treatment of myasthenia gravis in patients with an inadequate response to glucocorticoid therapy: randomized, double-blind, placebo-controlled study conducted in China. Ther Adv Neurol Disord. 2017;10(9):315\u201325. https:\/\/doi.org\/10.1177\/1756285617721092.","journal-title":"Ther Adv Neurol Disord."},{"issue":"1\u20132","key":"609_CR7","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jns.2010.09.033","volume":"300","author":"N Minami","year":"2011","unstructured":"Minami N, Fujiki N, Doi S, Shima K, Niino M, Kikuchi S, et al. Five-year follow-up with low-dose tacrolimus in patients with myasthenia gravis. J Neurol Sci. 2011;300(1\u20132):59\u201362. https:\/\/doi.org\/10.1016\/j.jns.2010.09.033.","journal-title":"J Neurol Sci."},{"issue":"9","key":"609_CR8","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1136\/jnnp-2011-300148","volume":"82","author":"H Yoshikawa","year":"2011","unstructured":"Yoshikawa H, Kiuchi T, Saida T, Takamori M. Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis. J Neurol Neurosurg Psychiatry. 2011;82(9):970\u20137. https:\/\/doi.org\/10.1136\/jnnp-2011-300148.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"37","key":"609_CR9","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.3760\/cma.j.issn.0376-2491.2017.37.001","volume":"97","author":"WB Liu","year":"2017","unstructured":"Liu WB. The innovation of international consensus guidance for management of myasthenia gravis (2016) and its practice in China. Zhonghua Yi Xue Za Zhi. 2017;97(37):2881\u20133. https:\/\/doi.org\/10.3760\/cma.j.issn.0376-2491.2017.37.001.","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"4","key":"609_CR10","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016;87(4):419\u201325. https:\/\/doi.org\/10.1212\/WNL.0000000000002790.","journal-title":"Neurology."},{"issue":"1","key":"609_CR11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/nyas.13544","volume":"1413","author":"H Murai","year":"2018","unstructured":"Murai H, Utsugisawa K, Nagane Y, Suzuki S, Imai T, Motomura M. Rationale for the clinical guidelines for myasthenia gravis in Japan. Ann N Y Acad Sci. 2018;1413(1):35\u201340. https:\/\/doi.org\/10.1111\/nyas.13544.","journal-title":"Ann N Y Acad Sci."},{"issue":"1","key":"609_CR12","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/nyas.13503","volume":"1412","author":"J Sussman","year":"2018","unstructured":"Sussman J, Farrugia ME, Maddison P, Hill M, Leite MI, Hilton-Jones D. The Association of British Neurologists' myasthenia gravis guidelines. Ann N Y Acad Sci. 2018;1412(1):166\u20139. https:\/\/doi.org\/10.1111\/nyas.13503.","journal-title":"Ann N Y Acad Sci."},{"issue":"6","key":"609_CR13","doi-asserted-by":"publisher","first-page":"404","DOI":"10.2165\/00003088-199529060-00003","volume":"29","author":"R Venkataramanan","year":"1995","unstructured":"Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet. 1995;29(6):404\u201330. https:\/\/doi.org\/10.2165\/00003088-199529060-00003.","journal-title":"Clin Pharmacokinet."},{"issue":"10","key":"609_CR14","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2165\/00003088-200443100-00001","volume":"43","author":"CE Staatz","year":"2004","unstructured":"Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004;43(10):623\u201353. https:\/\/doi.org\/10.2165\/00003088-200443100-00001.","journal-title":"Clin Pharmacokinet."},{"issue":"4","key":"609_CR15","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s40262-017-0567-8","volume":"57","author":"LM Andrews","year":"2018","unstructured":"Andrews LM, Hesselink DA, van Gelder T, Koch B, Cornelissen E, Bruggemann R, et al. A population pharmacokinetic model to predict the individual starting dose of tacrolimus following pediatric renal transplantation. Clin Pharmacokinet. 2018;57(4):475\u201389. https:\/\/doi.org\/10.1007\/s40262-017-0567-8.","journal-title":"Clin Pharmacokinet."},{"issue":"3","key":"609_CR16","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","volume":"41","author":"M Brunet","year":"2019","unstructured":"Brunet M, van Gelder T, Asberg A, Haufroid V, Hesselink DA, Langman L, et al. Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report. Ther Drug Monit. 2019;41(3):261\u2013307. https:\/\/doi.org\/10.1097\/FTD.0000000000000640.","journal-title":"Ther Drug Monit."},{"issue":"6","key":"609_CR17","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1177\/0091270003253624","volume":"43","author":"EI Ette","year":"2003","unstructured":"Ette EI, Williams PJ, Kim YH, Lane JR, Liu MJ, Capparelli EV. Model appropriateness and population pharmacokinetic modeling. J Clin Pharmacol. 2003;43(6):610\u201323.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"609_CR18","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1023\/A:1011555016423","volume":"28","author":"Y Yano","year":"2001","unstructured":"Yano Y, Beal SL, Sheiner LB. Evaluating pharmacokinetic\/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn. 2001;28(2):171\u201392.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"3","key":"609_CR19","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/bcp.13838","volume":"85","author":"LM Andrews","year":"2019","unstructured":"Andrews LM, Hesselink DA, van Schaik R, van Gelder T, de Fijter JW, Lloberas N, et al. A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients. Br J Clin Pharmacol. 2019;85(3):601\u201315. https:\/\/doi.org\/10.1111\/bcp.13838.","journal-title":"Br J Clin Pharmacol."},{"issue":"8","key":"609_CR20","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1038\/aps.2016.174","volume":"38","author":"YS Chen","year":"2017","unstructured":"Chen YS, Liu ZQ, Chen R, Wang L, Huang L, Zhu X, et al. Population pharmacokinetic analysis of tacrolimus in Chinese myasthenia gravis patients. Acta Pharmacol Sin. 2017;38(8):1195\u2013204. https:\/\/doi.org\/10.1038\/aps.2016.174.","journal-title":"Acta Pharmacol Sin."},{"issue":"2","key":"609_CR21","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/ene.13189","volume":"24","author":"T Kanai","year":"2017","unstructured":"Kanai T, Uzawa A, Kawaguchi N, Himuro K, Oda F, Ozawa Y, et al. Adequate tacrolimus concentration for myasthenia gravis treatment. Eur J Neurol. 2017;24(2):270\u20135. https:\/\/doi.org\/10.1111\/ene.13189.","journal-title":"Eur J Neurol."},{"key":"609_CR22","unstructured":"Siemens Healthcare Diagnosis Global Website. Viva-E System Gold-standard drug-testing performance with EMIT technology. https:\/\/www.siemens-healthineers.com\/drug-testing-diagnostics\/viva-drug-testing\/viva-pro-e-system. Accessed 25 Sept 2019."},{"issue":"11","key":"609_CR23","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1007\/s00228-008-0520-8","volume":"64","author":"XY Qiu","year":"2008","unstructured":"Qiu XY, Jiao Z, Zhang M, Zhong LJ, Liang HQ, Ma CL, et al. Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients. Eur J Clin Pharmacol. 2008;64(11):1069\u201384. https:\/\/doi.org\/10.1007\/s00228-008-0520-8.","journal-title":"Eur J Clin Pharmacol."},{"issue":"2","key":"609_CR24","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s00228-012-1330-6","volume":"69","author":"W Zhao","year":"2013","unstructured":"Zhao W, Fakhoury M, Baudouin V, Storme T, Maisin A, Deschenes G, et al. Population pharmacokinetics and pharmacogenetics of once daily prolonged-release formulation of tacrolimus in pediatric and adolescent kidney transplant recipients. Eur J Clin Pharmacol. 2013;69(2):189\u201395. https:\/\/doi.org\/10.1007\/s00228-012-1330-6.","journal-title":"Eur J Clin Pharmacol."},{"issue":"2","key":"609_CR25","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143\u201351. https:\/\/doi.org\/10.1208\/s12248-011-9255-z.","journal-title":"AAPS J."},{"issue":"5","key":"609_CR26","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1177\/00912700122010429","volume":"41","author":"R Venkataramanan","year":"2001","unstructured":"Venkataramanan R, Shaw LM, Sarkozi L, Mullins R, Pirsch J, MacFarlane G, et al. Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients. J Clin Pharmacol. 2001;41(5):542\u201351. https:\/\/doi.org\/10.1177\/00912700122010429.","journal-title":"J Clin Pharmacol."},{"issue":"6","key":"609_CR27","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1111\/jcpt.12599","volume":"42","author":"B Chen","year":"2017","unstructured":"Chen B, Shi HQ, Liu XX, Zhang WX, Lu JQ, Xu BM, et al. Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in Chinese liver transplant patients. J Clin Pharm Ther. 2017;42(6):679\u201388. https:\/\/doi.org\/10.1111\/jcpt.12599.","journal-title":"J Clin Pharm Ther."},{"issue":"3","key":"609_CR28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11095-019-2579-6","volume":"36","author":"T Lu","year":"2019","unstructured":"Lu T, Zhu X, Xu S, Zhao M, Huang X, Wang Z, et al. Dosage optimization based on population pharmacokinetic analysis of tacrolimus in chinese patients with nephrotic syndrome. Pharm Res-Dordr. 2019;36(3):45. https:\/\/doi.org\/10.1007\/s11095-019-2579-6.","journal-title":"Pharm Res-Dordr."},{"issue":"1","key":"609_CR29","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/FTD.0b013e31829f1ab8","volume":"36","author":"TK Bergmann","year":"2014","unstructured":"Bergmann TK, Hennig S, Barraclough KA, Isbel NM, Staatz CE. Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose. Ther Drug Monit. 2014;36(1):62\u201370. https:\/\/doi.org\/10.1097\/FTD.0b013e31829f1ab8.","journal-title":"Ther Drug Monit."},{"issue":"1","key":"609_CR30","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00228-012-1296-4","volume":"69","author":"N Han","year":"2013","unstructured":"Han N, Yun HY, Hong JY, Kim IW, Ji E, Hong SH, et al. Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients. Eur J Clin Pharmacol. 2013;69(1):53\u201363. https:\/\/doi.org\/10.1007\/s00228-012-1296-4.","journal-title":"Eur J Clin Pharmacol."},{"issue":"6","key":"609_CR31","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1067\/mcp.2002.129304","volume":"72","author":"CE Staatz","year":"2002","unstructured":"Staatz CE, Willis C, Taylor PJ, Tett SE. Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. Clin Pharmacol Ther. 2002;72(6):660\u20139. https:\/\/doi.org\/10.1067\/mcp.2002.129304.","journal-title":"Clin Pharmacol Ther."},{"issue":"2","key":"609_CR32","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1053\/jlts.2003.50023","volume":"9","author":"CE Staatz","year":"2003","unstructured":"Staatz CE, Willis C, Taylor PJ, Lynch SV, Tett SE. Toward better outcomes with tacrolimus therapy: population pharmacokinetics and individualized dosage prediction in adult liver transplantation. Liver Transpl. 2003;9(2):130\u20137. https:\/\/doi.org\/10.1053\/jlts.2003.50023.","journal-title":"Liver Transpl."},{"issue":"3","key":"609_CR33","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2165\/11594760-000000000-00000","volume":"51","author":"C Monchaud","year":"2012","unstructured":"Monchaud C, de Winter BC, Knoop C, Estenne M, Reynaud-Gaubert M, Pison C, et al. Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation. Clin Pharmacokinet. 2012;51(3):175\u201386. https:\/\/doi.org\/10.2165\/11594760-000000000-00000.","journal-title":"Clin Pharmacokinet."},{"key":"609_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00854-1","author":"MA Sikma","year":"2019","unstructured":"Sikma MA, Van Maarseveen EM, Hunault CC, Moreno JM, Van de Graaf EA, Kirkels JH, et al. Unbound plasma, total plasma, and whole-blood tacrolimus pharmacokinetics early after thoracic organ transplantation. Clin Pharmacokinet. 2019. https:\/\/doi.org\/10.1007\/s40262-019-00854-1.","journal-title":"Clin Pharmacokinet."},{"issue":"5\u20136","key":"609_CR35","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1159\/000331856","volume":"88","author":"L Xue","year":"2011","unstructured":"Xue L, Zhang H, Ma S, Rui JZ, Miao LY. Population pharmacokinetics and pharmacogenetics of tacrolimus in healthy Chinese volunteers. Pharmacology. 2011;88(5\u20136):288\u201394. https:\/\/doi.org\/10.1159\/000331856.","journal-title":"Pharmacology"},{"issue":"5","key":"609_CR36","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/j.1365-2710.2010.01206.x","volume":"36","author":"XJ Shi","year":"2011","unstructured":"Shi XJ, Geng F, Jiao Z, Cui XY, Qiu XY, Zhong MK. Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis. J Clin Pharm Ther. 2011;36(5):614\u201324. https:\/\/doi.org\/10.1111\/j.1365-2710.2010.01206.x.","journal-title":"J Clin Pharm Ther."},{"key":"609_CR37","unstructured":"FDA. (FDA) UFaDA. Prograf\u00ae: tacrolimus capsules\/tacrolimus injection (for intravenous infusion only). 2009. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/050708s027,050709s021lbl.pdf. Accessed 25 Jan 2020. (Revised May 2009)"},{"issue":"5","key":"609_CR38","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/bcpt.12176","volume":"114","author":"N Han","year":"2014","unstructured":"Han N, Ha S, Yun H, Kim MG, Min S, Ha J, et al. Population pharmacokinetic-pharmacogenetic model of tacrolimus in the early period after kidney transplantation. Basic Clin Pharmacol. 2014;114(5):400\u20136. https:\/\/doi.org\/10.1111\/bcpt.12176.","journal-title":"Basic Clin Pharmacol."},{"key":"609_CR39","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00846-1","author":"MA Sikma","year":"2019","unstructured":"Sikma MA, Hunault CC, Huitema A, De Lange DW, Van Maarseveen EM. Clinical pharmacokinetics and impact of hematocrit on monitoring and dosing of tacrolimus early after heart and lung transplantation. Clin Pharmacokinet. 2019. https:\/\/doi.org\/10.1007\/s40262-019-00846-1.","journal-title":"Clin Pharmacokinet."},{"issue":"10","key":"609_CR40","doi-asserted-by":"publisher","first-page":"683","DOI":"10.2165\/11535950-000000000-00000","volume":"49","author":"K Benkali","year":"2010","unstructured":"Benkali K, Rostaing L, Premaud A, Woillard JB, Saint-Marcoux F, Urien S, et al. Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation. Clin Pharmacokinet. 2010;49(10):683\u201392. https:\/\/doi.org\/10.2165\/11535950-000000000-00000.","journal-title":"Clin Pharmacokinet."},{"issue":"8","key":"609_CR41","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1111\/bcp.13960","volume":"85","author":"C Riff","year":"2019","unstructured":"Riff C, Debord J, Monchaud C, Marquet P, Woillard JB. Population pharmacokinetic model and Bayesian estimator for 2 tacrolimus formulations in adult liver transplant patients. Br J Clin Pharmacol. 2019;85(8):1740\u201350. https:\/\/doi.org\/10.1111\/bcp.13960.","journal-title":"Br J Clin Pharmacol."},{"issue":"4","key":"609_CR42","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/j.1365-2125.2007.02922.x","volume":"64","author":"HW Xin","year":"2007","unstructured":"Xin HW, Wu XC, Li Q, Yu AR, Zhu M, Shen Y, et al. Effects of Schisandra sphenanthera extract on the pharmacokinetics of tacrolimus in healthy volunteers. Br J Clin Pharmacol. 2007;64(4):469\u201375. https:\/\/doi.org\/10.1111\/j.1365-2125.2007.02922.x.","journal-title":"Br J Clin Pharmacol."},{"issue":"1\u20132","key":"609_CR43","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ijpharm.2010.01.025","volume":"389","author":"XL Qin","year":"2010","unstructured":"Qin XL, Bi HC, Wang XD, Li JL, Wang Y, Xue XP, et al. Mechanistic understanding of the different effects of Wuzhi Tablet (Schisandra sphenanthera extract) on the absorption and first-pass intestinal and hepatic metabolism of Tacrolimus (FK506). Int J Pharm. 2010;389(1\u20132):114\u201321. https:\/\/doi.org\/10.1016\/j.ijpharm.2010.01.025.","journal-title":"Int J Pharm."},{"issue":"11","key":"609_CR44","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1124\/dmd.117.076737","volume":"45","author":"J Li","year":"2017","unstructured":"Li J, Chen S, Qin X, Fu Q, Bi H, Zhang Y, et al. Wuzhi tablet (Schisandra sphenanthera extract) is a promising tacrolimus-sparing agent for renal transplant recipients who are cyp3a5 expressers: a two-phase prospective study. Drug Metab Dispos. 2017;45(11):1114\u20139. https:\/\/doi.org\/10.1124\/dmd.117.076737.","journal-title":"Drug Metab Dispos."},{"issue":"5","key":"609_CR45","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.phymed.2013.12.006","volume":"21","author":"XL Qin","year":"2014","unstructured":"Qin XL, Chen X, Zhong GP, Fan XM, Wang Y, Xue XP, et al. Effect of Tacrolimus on the pharmacokinetics of bioactive lignans of Wuzhi tablet (Schisandra sphenanthera extract) and the potential roles of CYP3A and P-gp. Phytomedicine. 2014;21(5):766\u201372. https:\/\/doi.org\/10.1016\/j.phymed.2013.12.006.","journal-title":"Phytomedicine"},{"issue":"6","key":"609_CR46","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1111\/j.1365-2125.2011.04039.x","volume":"72","author":"C Passey","year":"2011","unstructured":"Passey C, Birnbaum AK, Brundage RC, Oetting WS, Israni AK, Jacobson PA. Dosing equation for tacrolimus using genetic variants and clinical factors. Br J Clin Pharmacol. 2011;72(6):948\u201357. https:\/\/doi.org\/10.1111\/j.1365-2125.2011.04039.x.","journal-title":"Br J Clin Pharmacol."}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-020-00609-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13318-020-00609-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-020-00609-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,13]],"date-time":"2021-03-13T00:21:12Z","timestamp":1615594872000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13318-020-00609-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,13]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["609"],"URL":"https:\/\/doi.org\/10.1007\/s13318-020-00609-5","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,13]]},"assertion":[{"value":"13 March 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This work was supported by grants from the National Natural Science Foundation of China (No. 81573505), the \u2018Weak Discipline Construction Project\u2019 from the Shanghai Municipal Commission of Health and Family Planning (No. 2016ZB0301-01), the Shanghai Municipal Commission of Health and Family Planning (No. 20164Y0238), the finance of reserve talents from Shanghai Jing'an district Municipal Commission of Health and Family Planning and the \u2018Scientific Research Project\u2019 supported by the Huashan Hospital, Fudan University (No. 2014QD08).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Jue Liu, Yun-Peng Guo, Zheng Jiao, Chong-Bo Zhao, Hui Wu, Zi-Ran Li and Jian-Ying Xi declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All protocols were approved by the Medical Ethics Committee of Huashan Hospital (reference No. KY2016-271).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Iinformed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}